glp 1 drugs for inflammation Low Dose GLP-1 Inflammation: Evidence and Safety Frontiers | GLP-1 Receptor Agonists:

Volume on the primary search term has climbed from roughly 27,000 searches per month in late 2025 to over 60,000 per month in 2026, which tells you exactly how quickly this category is moving

Mehta D, Jackson R, Paul G, Shi J, Sabbagh M

Mechanistically, alterations in gut microbial metabolites such as SCFAs could affect the integrity of the BBB, induce systemic endotoxemia, and activate microglia so as to impact disease progression

Lp(a) can bind to fibrin and defensins that are released by neutrophils during infections or inflammation

and they will be there until your program exits

Targeting microbial pathways with drugs or phages A nascent but exciting area is using targeted therapies to modulate the microbiome without necessarily adding anything new